Regeneron’s New Ebola Treatment Just Received FDA Approval

Photo courtesy of Regeneron

Developed with the same methods as President Trump’s COVID-19 drug, the antibody cocktail could be a huge leap forward in helping eradicate the deadly virus.

Regeneron Pharmaceuticals, Inc. has announced that it has been granted approval from the U.S. Food and Drug Administration (FDA) to distribute Inmazeb, a multiple antibody cocktail aimed at treating the Zaire ebolavirus.

Ebola is known to cause internal bleeding and eventually death and caused an epidemic in Africa from 2013 to 2016 and had spread to other countries such as the United States. The disease resurfaced in 2018 in the Democratic Republic of the Congo, prompting Regeneron to take action to find a better solution, resulting in producing Inmazeb.


Read More: Regeneron Develops Promising New Ebola Treatment


Inmazeb, known as REGN-EB3, is a concoction of three antibodies that aims to treat the ebolavirus infection in adult and pediatric patients. Through a series of trials, Regeneron found that Inmazeb proved to be more effective and with a lower mortality rate than the current gold standard treatment, ZMapp.

- Advertisement -

“We are incredibly proud that the FDA has approved Inmazeb, which is also known as REGN-EB3. This is the first time the FDA has approved a treatment specifically for Ebola, which has caused a number of deadly outbreaks,” says George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron.

Regeneron is working with the Biomedical Advanced Research and Development Authority (BARDA) to administer Inmazeb doses to patients over the span of six years. This plan is set to satisfy the U.S. Department of Health and Human Services’ (HHS) wishes to build awareness and prepare for widespread disease outbreaks.

“We are moved to know our therapy is helping save the lives of people facing this deadly infectious disease,” says Regeneron’s Executive Vice President of Research and Development, Neil Stahl, Ph.D. “We look forward to working with governments and other collaborators, including BARDA, to make REGN-EB3 available for the current outbreak and future use.”

If the phrase “multiple antibody cocktail” seems familiar, it should: Regeneron’s work in developing Inmazeb utilized the same new development process used in the development of REGN-COV2, the antibody treatment given to U.S. President Donald Trump just a few weeks ago, leading to his apparent speedy recovery from COVID-19 infection.


Read More: Regeneron’s New COVID-19 Treatment Could Be Ready Sooner Than You Think

Unveiled: A Boutique Bridal Brunch is February 23!

Our Best of Westchester Readers' Ballot is open through January 15!

Our Women in Business Awards event is November 21!

Our Best of Business event is October 30!

Our CEOs & Business Leaders Golf Outing is August 5!

Our Best of Westchester Party is July 24!

Our Westchester Home Design Awards event is June 26!

Our Wine & Food Festival returns June 4-9!

Our Wunderkinds event takes place on May 23!

Our Best of Business Ballot is open through May 15!

Our Healthcare Heroes Awards event takes place on May 9!

Our Westchester Home Builders Awards take place on April 4!

Our Diversity, Equity & Inclusion Forum is March 14!

Holiday flash sale ... subscribe and save 50%

Limited time offer. New subscribers only.